Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.
Scully IL, McNeil LK, Pathirana S, Singer CL, Liu Y, Mullen S, Girgenti D, Gurtman A, Pride MW, Jansen KU, Huang PL, Anderson AS. Scully IL, et al. Among authors: pride mw. Diabetol Metab Syndr. 2024 Mar 25;16(1):76. doi: 10.1186/s13098-024-01314-y. Diabetol Metab Syndr. 2024. PMID: 38528575 Free PMC article. No abstract available.
A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Senders S, Klein NP, Tamimi N, Thompson A, Baugher G, Trammel J, Peng Y, Giardina P, Scully IL, Pride M, Center KJ, Gruber WC, Scott DA, Watson W. Senders S, et al. Pediatr Infect Dis J. 2024 Jun 1;43(6):596-603. doi: 10.1097/INF.0000000000004334. Epub 2024 Mar 26. Pediatr Infect Dis J. 2024. PMID: 38535409 Free PMC article. Clinical Trial.
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.
Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K, Wilcox MH, Lawrence J, Bouguermouh S, Zhang H, Koury K, Bailey R, Smith HM, Lockhart S, Lamberth E, Kalina WV, Pride MW, Webber C, Anderson AS, Jansen KU, Gruber WC, Kitchin N. Donskey CJ, et al. Among authors: pride mw. Clin Infect Dis. 2024 Dec 17;79(6):1503-1511. doi: 10.1093/cid/ciae410. Clin Infect Dis. 2024. PMID: 39180325 Free PMC article. Clinical Trial.
Streptococcus pneumoniae Serotype Distribution Among US Adults Hospitalized With Community-Acquired Pneumonia, 2019-2020.
Ramirez JA, Hubler RA, Ali M, Gray SL, Carrico R, McNaughton CD, Wunderink RG, Dela Cruz CS, Chilson EL, Cané AD, Isturiz RE, Pride MW, Jodar L, Gessner BD, Grant LR. Ramirez JA, et al. Among authors: pride mw. Open Forum Infect Dis. 2024 Dec 17;12(1):ofae727. doi: 10.1093/ofid/ofae727. eCollection 2025 Jan. Open Forum Infect Dis. 2024. PMID: 39758745 Free PMC article.
Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates cultured from Japanese adult patients with community-acquired pneumonia in Goto City, Japan.
Miyazaki T, van der Linden M, Hirano K, Maeda T, Kohno S, Gonzalez EN, Zhang P, Isturiz RE, Gray SL, Grant LR, Pride MW, Gessner BD, Jodar L, Arguedas AG. Miyazaki T, et al. Among authors: pride mw. Front Microbiol. 2024 Sep 24;15:1458307. doi: 10.3389/fmicb.2024.1458307. eCollection 2024. Front Microbiol. 2024. PMID: 39380682 Free PMC article.
Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
Hyams C, Lahuerta M, Theilacker C, King J, Adegbite D, McGuinness S, Grimes C, Campling J, Southern J, Pride MW, Begier E, Maskell N, Oliver J, Jodar L, Gessner BD, Finn A; AvonCAP Research Group. Hyams C, et al. Among authors: pride mw. Vaccine. 2024 Mar 7;42(7):1599-1607. doi: 10.1016/j.vaccine.2024.02.007. Epub 2024 Feb 8. Vaccine. 2024. PMID: 38336560 Free article.
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
Christensen S, Bouguermouh S, Ilangovan K, Pride MW, Webber C, Lockhart SP, Shah R, Kitchin N, Lamberth E, Zhang H, Gao Q, Brock L, Anderson AS, Gruber WC. Christensen S, et al. Among authors: pride mw. Vaccine. 2023 Dec 7;41(50):7548-7559. doi: 10.1016/j.vaccine.2023.11.003. Epub 2023 Nov 17. Vaccine. 2023. PMID: 37977942 Free article. Clinical Trial.
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.
Remich S, Kitchin N, Peterson J, Li P, Pride MW, Brock L, Anderson AS, Gruber WC, Jansen KU, Lockhart SP, Webber C. Remich S, et al. Among authors: pride mw. J Infect Dis. 2024 Feb 14;229(2):367-375. doi: 10.1093/infdis/jiad307. J Infect Dis. 2024. PMID: 37531657 Free PMC article. Clinical Trial.
57 results